ZYLOXTB (02190) spent 1.123 million Hong Kong dollars to repurchase 51,000 shares on May 13th.
Return Across the Bridge (02190) announced that on May 13, 2026, it has spent 1.123 million Hong Kong dollars to repurchase 51,000 shares.
ZYLOXTB(02190) announced on May 13, 2026, that it will spend 1.123 million Hong Kong dollars to repurchase 51,000 shares.
Related Articles
.png)
XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.
Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.
CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.
XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.
Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.
CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
